av Suwan Kim 2 år siden
144
Mer som dette
Ved olivia we
Ved Catalina Carrillo
Ved Shweta Shah
Ved ricardo silva
Docetaxel + carboplatin + trastuzumab +/- pertuzumab Q21 days x6 cycles (TCH or TCHP)
Doxorubicin + Cyclophosphamide Q14/21 days x4 cycles
paclitaxel + trastuzumab +/- pertuzumab x 1 year
pembrolizumab + AC
pembrolizumab as maintenance
taxane
Endocrine therapy +/- Chemotherapy
Chemotherapy + anti-HER2 therapy + Endocrine therapy
Chemo + anti-HER2 options
Docetaxel + carboplatin + trastuzumab +/- pertuzumab Q21 days x6 cycles (TCH+/-P)
trastuzumab +/- pertuzumab x1 year
paclitaxel + trastuzumab +/- pertuzumab x 1 year (pertuzumab if node positive)
Endocrine options
CD4K inhibitors
Ribociclib Abemaciclib palbociclib
Ovarian ablation/suppression
Oophorectomy LH releasing agents
Goserelin leuprolide triptorelin
AI (POSTmenopausal)
Anastrozole Letrozole Exemestane
SERM
Tamoxifen(PREmenopausal)
HER2+
Chemotherapy + Anti-HER2 therapy
HER2-
Chemotherapy
Chemotherapy options
Taxane based
Docetaxel + Cyclophosphamide Q21 days x4 cycles (TC)
Anthracycline based
Doxorubicin + Cyclophosphamide Q14/21 days x4 cycles (AC)
paclitaxel weekly x12 weeks